Pluvicto 2026 - cleveland VAMC
Ended Awarded
- Contract number
- 36C25026F0205
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $617,297
Award facts
- Contract value 100% obligated
- $617,296.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 10, awarded a delivery order valued at $617,296.68 to Novartis Pharmaceuticals Corporation on January 20, 2026, for the supply of PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical cancer therapy product. This firm fixed-price delivery order, with completion expected by June 30, 2026, was issued without a small business set-aside designation and falls under Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The award supports the VA's mission to provide advanced oncology treatments to veterans through the Cleveland VA Medical Center, with product delivery to Novartis' East Hanover, New Jersey facility.
This delivery order is issued under a larger single-award Blanket Purchase Agreement valued at $7.48 million that Veterans Integrated Service Network 10 established with Novartis on October 1, 2025, for PLUVICTO procurement extending through September 30, 2030. Novartis, a foreign-owned pharmaceutical manufacturer headquartered in East Hanover, New Jersey, serves as a major federal supplier of specialized cancer therapies and radiopharmaceuticals to the Department of Veterans Affairs and Defense Health Agency. The company competes directly in the federal marketplace as a large manufacturer and holds registration in SAM.gov through June 20, 2026, leveraging its extensive federal contract portfolio across multiple Veterans Integrated Service Networks and defense healthcare systems to deliver critical oncology treatments supporting veteran care programs.
Quick answers
Who was awarded contract 36C25026F0205?
36C25026F0205 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 10 (Veterans Health Administration) on January 20, 2026.
How much is contract 36C25026F0205 worth?
The government has obligated $617,297 on 36C25026F0205.
Is contract 36C25026F0205 an order under another contract?
Yes. 36C25026F0205 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25026F0205 competed?
The extent of competition for 36C25026F0205 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award